Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The
antibody–drug conjugate linker molecule determines both the efficacy and the adverse …

Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to
preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by …

Proteins are multifunctional large organic compounds that constitute an essential
component of a living system. Hence, control over their bioconjugation impacts science at …

Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug
conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while …

Systemic chemotherapy, the current standard of care for the treatment of cancer, is rarely
curative and is often accompanied by debilitating side effects. Targeted drug delivery stands …

Conventional antibody–drug conjugates (ADCs) are heterogeneous mixtures of chemically
distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal …

The increasing development of targeted cancer therapy provides extensive possibilities in
clinical trials, and numerous strategies have been explored. The prodrug is one of the most …

Due to their remarkable selectivity and specificity for cancer biomarkers, immunoconjugates
have emerged as extremely promising vectors for the delivery of diagnostic radioisotopes …

Glioblastoma multiforme (GBM) is the most aggressive and fatal disease of all brain tumor
types. Most therapies rarely provide clinically meaningful outcomes in the treatment of GBM …

Conjugates between proteins and small molecules enable access to a vast chemical space
that is not achievable with either type of molecule alone; however, the paucity of specific …